Peptide FAQs

One question. One paragraph. The evidence and its limitations, together.

Primary investigators
80 answers
BPC-157Does BPC-157 speed tendon or ligament healing?
Quick answer:
Study-specific; no cross-route equivalence assumed.[1][2]

The knee-pain case series measured subjective symptoms, without objective confirmation of tendon or ligament repair.[1] In a 2026 rat Achilles-repair experiment, BPC-157 alone did not significantly improve maximum load to failure versus control.[2] That experiment used four tendons per group for each endpoint, so its nonsignificant result does not establish that no effect exists.[2] Pain relief and tissue repair are different outcomes: a report of less pain does not show that a torn tendon has regained its structure or mechanical strength.[1] The rat experiment assessed surgically repaired Achilles tendons, so it also cannot determine whether BPC-157 accelerates recovery from the range of tendon injuries seen in clinical practice.[2]

Key limitation: Symptoms and preclinical endpoints do not establish human structural repair.[1][2]
Read in the peptide guide
BPC-157What does the human knee-pain study show?
Quick answer:
Study-specific; no cross-route equivalence assumed.[1]

Of seventeen patients identified, sixteen were contacted; eleven of twelve receiving BPC-157 alone reported improvement.[1] The uncontrolled, retrospective design and subjective outcomes cannot separate a drug effect from recovery, expectation or other care.[1] The patients had different types of knee pain, and the study did not include a comparable group receiving placebo or usual care alone.[1] The finding is therefore a preliminary signal of reported symptom improvement, rather than evidence that BPC-157 treats a defined knee disorder or repairs damaged cartilage.[1]

Key limitation: No placebo or objective repair endpoint.[1]
Read in the peptide guide
BPC-157What evidence supports muscle-injury recovery?
Quick answer:
Study-specific; no cross-route equivalence assumed.[3][4][5]

Rat experiments reported improved muscle-to-bone reattachment and recovery after muscle–tendon junction separation.[3][4] A separate rat muscle-crush experiment reported improved healing during corticosteroid exposure.[5] These induced injuries support further research but do not establish human recovery times, effective doses or safe drug combinations.[3][4][5] The experiments address different injuries and treatment conditions, making their results specific to those models rather than a single, established effect on muscle recovery.[3][4][5] They do not answer whether an athlete or a patient undergoing rehabilitation would regain strength sooner, return to activity earlier, or experience fewer complications.[3][4][5]

Key limitation: No direct human muscle-recovery trial in these studies.[3][4][5]
Read in the peptide guide
BPC-157Does BPC-157 heal the gut or treat inflammatory bowel disease?
Quick answer:
Study-specific; no cross-route equivalence assumed.[6][7][8]

Studies in animals report reduced injury in rat models of gastric ulcers and concentrated-alcohol exposure.[6][7] FDA separately reviewed a small placebo-controlled ulcerative-colitis study reported only as a meeting abstract, with insufficient detail for a reliable effectiveness assessment.[8] Those findings do not establish a benefit for commercial oral BPC-157 products or nonspecific “leaky gut” symptoms.[6][8] Damage caused experimentally by concentrated alcohol is a different research problem from treating chronic inflammatory bowel disease in people.[7] The animal results provide a reason to investigate gastrointestinal effects, but the incomplete human report does not establish which patients would benefit, how large the benefit would be, or whether it would persist.[6][7][8]

Key limitation: Human evidence includes an incompletely reported meeting abstract, with insufficient detail to assess effectiveness reliably.[6][7][8]
Read in the peptide guide
BPC-157Has BPC-157 been studied for bladder pain?
Quick answer:
Study-specific; no cross-route equivalence assumed.[9]

An uncontrolled retrospective report described twelve women treated by cystoscopic bladder injection; ten reported complete symptom resolution and two partial improvement.[9] The paper describes follow-up timing inconsistently, and the lack of a comparator prevents attributing improvement to BPC-157.[9] This procedure-specific report does not establish that oral or subcutaneous products treat bladder pain.[9] The small sample and retrospective symptom assessments make this an exploratory observation, not a controlled estimate of treatment benefit.[9] Its findings apply to the particular patients and bladder procedure described, and cannot supply a general treatment protocol for urinary symptoms.[9]

Key limitation: No comparator; inconsistent timing; route-specific procedure.[9]
Read in the peptide guide
BPC-157Does the large clinical-note study prove BPC-157 works?
Quick answer:
Study-specific; no cross-route equivalence assumed.[10]

A September 2026 preprint identified 1,039 documented users; 279 of the 354 with a recorded response direction had reported improvement, while 685 lacked a recorded response direction.[10] It was not peer reviewed at this check, and missing outcomes, co-treatments and no control group prevent interpreting these counts as an effectiveness rate.[10] The much larger number of documented users improves the description of real-world use, but it does not resolve the missing outcomes or introduce the comparison group needed to estimate a treatment effect.[10]

Key limitation: Selection, missingness and confounding.[10]
Read in the peptide guide
BPC-157Has BPC-157 been shown to be safe in humans?
Quick answer:
Study-specific; no cross-route equivalence assumed.[10][11]

The two-person intravenous pilot reported no adverse effects during three days of monitoring, but both participants had previous exposure.[11] This small, selected sample cannot establish routine or long-term safety.[11] The clinical-note preprint also describes neuropsychiatric, skin or injection-site, and gastrointestinal symptoms, without establishing causation or reliable event rates.[10] Three days of observation in two previously exposed adults provides little information about uncommon reactions, the consequences of repeated treatment, or effects that emerge after prolonged exposure.[11] The larger clinical-note report adds descriptions of symptoms encountered in practice, but its retrospective records cannot reliably distinguish adverse drug reactions from symptoms associated with illness or other treatments.[10]

Key limitation: Brief monitoring and nonstandard adverse-event ascertainment.[10][11]
Read in the peptide guide
BPC-157Does BPC-157 increase growth hormone?
Quick answer:
Study-specific; no cross-route equivalence assumed.[12]

A cell-culture study found increased growth-hormone receptor expression in rat tendon fibroblasts.[12] That is different from demonstrating increased circulating growth hormone, and it does not validate combining BPC-157 with growth-hormone secretagogues in people.[12] Receptors describe how a cell may respond to a hormone; this experiment did not measure a rise in blood growth-hormone levels or test a clinical benefit from raising those levels.[12]

Key limitation: Receptor expression is not systemic hormone concentration.[12]
Read in the peptide guide
BPC-157Does combining BPC-157 with TB-500 work better?
Quick answer:
Study-specific; no cross-route equivalence assumed.[1][2]

The knee case series included only four recipients of BPC-157 plus thymosin beta-4 and did not randomize treatment.[1] A rat Achilles study found no additional benefit from its BPC-157/TB-500 combination over monotherapy, with small endpoint samples.[2] Neither study establishes the benefit or safety of commercial peptide blends in people.[1][2]

Key limitation: Formulation and route cannot be generalized.[1][2]
Read in the peptide guide
BPC-157Does oral BPC-157 work as well as an injection?
Quick answer:
Study-specific; no cross-route equivalence assumed.[3][6][13]

Oral administration produced effects in some rat injury experiments, but those experiments did not measure clinical equivalence in humans.[3][6] A pharmacokinetic study examined intravenous and intramuscular administration in rats and dogs; it did not evaluate human oral absorption.[13] These sources do not establish that capsules and injections are interchangeable.[3][13] A response in an animal injury model and a measurement of drug exposure answer different questions; neither establishes that a marketed capsule delivers the same exposure or effects as an injection in a person.[3][6][13] Consequently, route-specific findings should remain attached to the formulation, species and administration method actually studied.[3][6][13]

Key limitation: Animal responses are not human bioavailability.[3][6][13]
Read in the peptide guide
BPC-157What is known about BPC-157’s half-life?
Quick answer:
Study-specific; no cross-route equivalence assumed.[11][13]

The pharmacokinetic paper reported mean intact-peptide half-lives below thirty minutes in tested rat and dog regimens.[13] The two-person human intravenous paper measured clinical laboratory markers rather than BPC-157 concentrations.[11] These studies therefore do not establish a human half-life or dosing frequency.[11][13] A short animal plasma half-life also does not, by itself, tell us how long a biological effect lasts or how frequently a person would need treatment.[13]

Key limitation: Intact peptide must be distinguished from total radiolabel.[11][13]
Read in the peptide guide
TB-500Is TB-500 the same as thymosin beta-4, and does it heal injuries?
Quick answer:
Marketed injectable fragment versus researched ophthalmic full-length peptide.[14][15]

The name TB-500 requires clarification before interpreting any study.[14] FDA describes TB-500 as the thymosin beta-4 fragment LKKTETQ and reports that it has not identified human exposure data for that fragment.[14] Full-length thymosin beta-4 has been studied in humans, including investigational eye drops for corneal disease, but that is a different molecule, formulation, target tissue, and route.[15] Those trials cannot validate a vial marketed as TB-500 for tendon repair or whole-body recovery.[14][15] For injury healing with the fragment, direct human clinical benefit remains unestablished in the evidence reviewed here.[14][15]

Key limitation: Molecular identity and route prevent extrapolation.[14][15]
Read in the peptide guide
GHK-CuDoes topical GHK-Cu improve skin quality?
Quick answer:
Topical copper-tripeptide skin-care regimen.[16]

The selected topical trial provides limited, procedure-specific evidence for GHK-Cu.[16] In a randomized study after carbon dioxide laser resurfacing, 13 patients completed follow-up.[16] Participants using the copper-peptide regimen reported greater improvement in overall skin quality, but objective assessments found no significant between-group improvement in wrinkles, overall skin quality, or resolution of redness.[16] This small, procedure-specific study does not establish that every copper-peptide serum reduces wrinkles or reverses skin aging.[16] Subjective satisfaction and objectively measured improvement should remain separate when judging a cosmetic claim, and findings from a topical regimen should not be transferred to injections.[16]

Key limitation: Small sample, mixed endpoints, procedure-specific context.[16]
Read in the peptide guide
GHK-CuIs injectable GHK-Cu better than a topical serum?
Quick answer:
Systemic injection versus topical application.[14][16]

Clinical superiority of injected GHK-Cu over topical GHK-Cu has not been demonstrated in the human evidence reviewed here.[14][16] A topical study cannot establish the effectiveness or safety of systemic injection, because exposure and delivery are different.[16] FDA identifies limited human safety data for injectable GHK-Cu and potential immunogenicity associated with aggregation and peptide impurities.[14] The argument that injection must work better because it bypasses the skin barrier is a mechanistic hypothesis, not a clinical result.[14][16] A useful comparison would require a controlled human study of defined formulations, relevant skin outcomes, and adverse events.[14][16]

Key limitation: A delivery hypothesis does not establish benefit or safety.[14][16]
Read in the peptide guide
CJC-1295Does raising growth hormone with CJC-1295 prove better recovery or muscle growth?
Quick answer:
Subcutaneous long-acting CJC-1295 in the cited trials.[17]

CJC-1295 has demonstrated hormonal activity in humans, but that does not establish improved recovery or muscle performance.[17] Two short randomized, placebo-controlled trials of the long-acting formulation found increases in growth hormone and IGF-1 in healthy adults.[17] These were pharmacology studies, not demonstrations of faster injury healing, greater strength, better sleep, or longer life.[17] A biomarker response is useful for understanding what a compound does, while meaningful benefit requires direct clinical outcomes.[17] Results from the studied long-acting molecule should also not be automatically assigned to products marketed as CJC-1295 without DAC or to combination products.[17]

Key limitation: GH and IGF-1 are surrogate outcomes for the proposed benefits.[17]
Read in the peptide guide
IpamorelinDoes ipamorelin, alone or with CJC-1295, improve sleep and recovery?
Quick answer:
Intravenous studies; subcutaneous combination claims not established.[18][19]

The human studies reviewed here do not establish that ipamorelin improves sleep quality or training recovery, either alone or combined with CJC-1295.[18][19] Early human work examined its pharmacokinetics and growth-hormone response, while a later randomized trial studied intravenous ipamorelin after bowel surgery.[18][19] Neither setting directly tests the sleep or recovery claims made for subcutaneous combinations.[18][19] Evidence that a compound stimulates growth hormone is not interchangeable with evidence of better sleep architecture, physical function, or recovery time.[18][19] A combination also requires its own evaluation rather than assuming that separate hormone effects add up to clinical benefit.[18][19]

Key limitation: No matched clinical-outcome trial identified for these claims.[18][19]
Read in the peptide guide
SemaglutideHow much weight loss did semaglutide produce in a major clinical trial?
Quick answer:
Studied subcutaneous pharmaceutical formulation.[20]

In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to subcutaneous semaglutide or placebo, both alongside lifestyle intervention.[20] At 68 weeks, average weight change was −14.9% with semaglutide and −2.4% with placebo.[20] This provides strong evidence of average weight reduction in the studied population, but it is not a forecast for an individual or evidence for an unverified research-use product.[20] Gastrointestinal adverse effects were common, and the trial used a defined pharmaceutical formulation under clinical supervision.[20] Its results should not be generalized to every dose, route, or patient group.[20]

Key limitation: Average trial response does not predict an individual's result.[20]
Read in the peptide guide
SemaglutideWhat happens to weight after stopping semaglutide?
Quick answer:
Withdrawal after studied subcutaneous semaglutide.[21]

Weight regain was substantial after treatment ended in the STEP 1 extension.[21] In the extension group, participants previously assigned semaglutide regained an average 11.6 percentage points of body weight during the following year, approximately two-thirds of their earlier loss, leaving an average net reduction of 5.6% from the original baseline.[21] This was follow-up of a subset of the original trial, and structured lifestyle intervention also stopped, so it cannot isolate every contributor to regain.[21] It nevertheless shows that a successful treatment period does not guarantee permanent weight maintenance after withdrawal.[21]

Key limitation: Selected follow-up subset; drug and lifestyle intervention both stopped.[21]
Read in the peptide guide
TirzepatideHow much weight loss did tirzepatide produce in SURMOUNT-1?
Quick answer:
Studied subcutaneous pharmaceutical formulation.[22]

SURMOUNT-1 randomized 2,539 adults with obesity, or overweight with a weight-related complication, without diabetes.[22] Across the three studied tirzepatide groups, average weight reduction at 72 weeks ranged from 15.0% to 20.9%, compared with 3.1% with placebo.[22] The size and randomized design support a strong conclusion about average weight reduction under the trial conditions.[22] Gastrointestinal adverse effects were the most common and occurred mainly during dose escalation.[22] These figures describe a specific pharmaceutical product, population, and treatment program; they do not establish equivalent effects for products of unknown composition or guarantee an individual response.[22]

Key limitation: Effects depend on the studied population and treatment conditions.[22]
Read in the peptide guide
TirzepatideDoes tirzepatide cause more weight loss than semaglutide?
Quick answer:
Subcutaneous trial formulations and maximum tolerated regimens.[23]

In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide in adults with obesity without diabetes.[23] Among 751 randomized participants, mean weight change at 72 weeks was −20.2% with tirzepatide and −13.7% with semaglutide, using the maximum tolerated trial regimens.[23] The trial was open-label and manufacturer funded, which should be considered alongside its direct randomized comparison.[23] Gastrointestinal adverse events were common in both groups.[23] The finding applies to the formulations and regimens compared; it does not prove that one medicine is the best choice for every individual or every clinical outcome.[23]

Key limitation: Open-label, manufacturer-funded, specific regimens and population.[23]
Read in the peptide guide
TirzepatideDo people regain weight when they stop tirzepatide?
Quick answer:
Continuation or withdrawal of subcutaneous tirzepatide.[24]

Many participants regained weight after tirzepatide withdrawal in SURMOUNT-4.[24] After a 36-week initial treatment period, 670 participants were randomized either to continue tirzepatide or switch to placebo.[24] During the next 52 weeks, the placebo group gained an average 14.0% relative to its weight at randomization, while those continuing tirzepatide lost a further 5.5%.[24] This is direct randomized evidence that continued treatment helped maintain weight reduction in participants who reached randomization.[24] It does not mean everybody regains the same amount, and its selected population excludes people who discontinued during the initial treatment phase.[24]

Key limitation: Enriched for participants able to reach randomization.[24]
Read in the peptide guide
Collagen peptidesDo oral collagen peptides help activity-related joint pain?
Quick answer:
Oral collagen hydrolysate.[25]

Oral collagen hydrolysate may improve some measures of activity-related joint discomfort, but the evidence is less decisive than marketing often suggests.[25] A 24-week randomized trial recruited 147 athletes and analyzed 97; several pain measures favored collagen over placebo.[25] The missing participants, multiple outcomes, and specific athletic population limit confidence and generalizability.[25] Reduced pain also does not demonstrate cartilage regeneration or accelerated repair of a torn tendon.[25] This result concerns an oral nutritional preparation with a particular composition, so it should not be used to justify injectable peptides or to assume that every collagen product is clinically equivalent.[25]

Key limitation: Attrition, multiple outcomes, and limited population applicability.[25]
Read in the peptide guide
Collagen peptidesDo oral collagen peptides improve skin elasticity?
Quick answer:
Oral collagen hydrolysate.[26]

A randomized trial reported improved skin elasticity with a specific oral collagen preparation.[26] In one double-blind trial, 69 women aged 35–55 were assigned collagen hydrolysate or placebo for eight weeks; elasticity improved relative to placebo, while moisture-related findings were not statistically significant.[26] This is a short-term signal in a narrow population rather than proof of broad skin rejuvenation.[26] Results depend on the product and endpoint, and statistical improvement does not automatically establish a noticeable cosmetic difference.[26] The trial does not support claims about injectable collagen-related peptides or permanent reversal of skin aging.[26]

Key limitation: Short duration, narrow population, and product-specific findings.[26]
Read in the peptide guide
SemaglutideDoes a 99% purity claim mean a peptide is safe to inject?
Quick answer:
Products sold for injection.[27]

A purity percentage does not establish correct identity, labeled amount, sterility, endotoxin control, or clinical safety.[27] In a 2024 test-purchase study of no-prescription online semaglutide, only three of six orders arrived.[27] The delivered samples contained more semaglutide than labeled, had reported purity far below the advertised 99%, and one contained elevated endotoxin despite no viable microorganisms being detected.[27] The sample was small and selected, so it cannot estimate the failure rate of the entire market.[27] It does demonstrate why a seller's percentage or certificate cannot, by itself, establish that a finished injectable product is suitable for human use.[27]

Key limitation: Documents failures; does not estimate market-wide prevalence.[27]
Read in the peptide guide
Semaglutide · SafetyWhat safety issues are established for Wegovy?
Quick answer:

The Wegovy label lists common reactions including nausea, vomiting, diarrhea and constipation; serious warnings include pancreatitis, gallbladder disease and dehydration-related kidney injury.[28] The thyroid-tumor warning comes from rodent findings whose relevance to humans is unknown.[28] The Medication Guide directs stopping treatment and seeking immediate help for persistent severe abdominal pain or serious allergic symptoms, including breathing difficulty or face/throat swelling.[28] Patients should disclose treatment before anesthesia or deep sedation because aspiration has been reported.[28]

Read in the peptide guide
Semaglutide · ContraindicationsWhat are the formal contraindications and separate precautions?
Quick answer:

The Wegovy label’s formal contraindications include personal/family medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and semaglutide/excipient hypersensitivity.[28] Separate pregnancy guidance for weight management directs discontinuation when pregnancy is recognized and at least two months before planned pregnancy.[28] Breastfeeding is not recommended with tablets; injection labeling calls for individualized assessment because milk-transfer and infant-effect data are missing.[28] Severe gastroparesis is a separate not-recommended precaution.[28]

Read in the peptide guide
Semaglutide · InteractionsWhich medication interactions require attention?
Quick answer:

Insulin and sulfonylureas can increase hypoglycemia risk; delayed gastric emptying may affect oral medicines, including those requiring close monitoring.[28]

Read in the peptide guide
Semaglutide · Forms & dosingWhich forms and administration instructions are covered?
Quick answer:

Wegovy tablets and subcutaneous injections have separate escalation, maintenance, administration and switching instructions.[28]

Read in the peptide guide
Semaglutide · Results & stoppingWhat does the label say about duration and treatment interruptions?
Quick answer:

Wegovy is labeled for long-term weight maintenance; its Medication Guide directs clinician discussion after multiple missed weekly injections.[28]

Read in the peptide guide
Semaglutide · Product qualityDo compounded products have the same quality evidence?
Quick answer:

FDA identifies semaglutide sodium and acetate as different active ingredients from those in approved drugs and says their chemical and pharmacologic equivalence is not established.[29] The agency has also received reports of dosing errors with compounded semaglutide injections, including cases requiring hospitalization.[29]

Read in the peptide guide
Semaglutide · StatusWhat does U.S. approval mean for this page?
Quick answer:

Wegovy has approved weight-management indications; eligibility and other indications differ between oral and injectable formulations.[28] Compounded semaglutide is not FDA-approved and does not undergo the agency's premarket review for safety, effectiveness and quality.[30]

Read in the peptide guide
Tirzepatide · SafetyWhat safety issues are established for Zepbound?
Quick answer:

The Zepbound label lists common reactions including nausea, vomiting, diarrhea and constipation; serious warnings include pancreatitis, gallbladder disease and dehydration-related kidney injury.[31] The thyroid-tumor warning comes from rodent findings whose relevance to humans is unknown.[31] The Medication Guide directs stopping treatment and seeking immediate help for persistent severe abdominal pain or serious allergic symptoms, including breathing difficulty or face/throat swelling.[31] Patients should disclose treatment before anesthesia or deep sedation because aspiration has been reported.[31]

Read in the peptide guide
Tirzepatide · ContraindicationsWhat are the formal contraindications and separate precautions?
Quick answer:

The Zepbound label’s formal contraindications include personal/family medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and serious tirzepatide/excipient hypersensitivity.[31] Separate pregnancy guidance directs discontinuation when pregnancy is recognized.[31] Breastfeeding requires benefit–risk assessment: infant and milk-production effects are unknown despite low milk transfer in a single-dose study.[31] Severe gastroparesis is a separate not-recommended precaution.[31]

Read in the peptide guide
Tirzepatide · InteractionsWhich medication interactions require attention?
Quick answer:

Insulin and sulfonylureas can increase hypoglycemia risk; delayed gastric emptying may affect oral-drug absorption.[31] Reduced oral contraceptive effectiveness requires additional precautions after initiation and dose escalation.[31]

Read in the peptide guide
Tirzepatide · Forms & dosingWhich forms and administration instructions are covered?
Quick answer:

Zepbound is injected subcutaneously weekly; pen/vial instructions and dosing depend on presentation, indication and tolerability.[31]

Read in the peptide guide
Tirzepatide · Results & stoppingWhat does the label say about duration and treatment interruptions?
Quick answer:

Zepbound is labeled for long-term weight maintenance; its prescribing information provides instructions for missed weekly doses.[31]

Read in the peptide guide
Tirzepatide · Product qualityDo compounded products have the same quality evidence?
Quick answer:

FDA reports fraudulent compounded tirzepatide labeling and concerns about shipping temperatures, dosing and dose escalation for unapproved GLP-1 products.[29] Compounded drugs can meet particular medical needs, but contamination or incorrect active-ingredient amounts can cause serious harm.[30]

Read in the peptide guide
Tirzepatide · StatusWhat does U.S. approval mean for this page?
Quick answer:

Zepbound is approved for weight management in eligible adults and moderate-to-severe obstructive sleep apnea in adults with obesity.[31] Compounded tirzepatide is not FDA-approved and has not undergone FDA premarket review for safety, effectiveness and quality.[30]

Read in the peptide guide
BPC-157 · SafetyWhat safety concerns does FDA identify?
Quick answer:

FDA identifies immunogenicity concerns and limited route-specific safety information.[14]

Read in the peptide guide
BPC-157 · ContraindicationsHas safety been established for pregnancy or people concerned about cancer?
Quick answer:

FDA's 2026 assessment identified no carcinogenicity studies and incomplete reproductive testing for the evaluated BPC-157 substances and routes.[8] Those gaps leave pregnancy and cancer-related safety unresolved; they do not establish either a proven-safe population or a demonstrated human cancer effect.[8] These are missing safety assessments, rather than evidence that every potential risk has been excluded.[8] The available assessment therefore cannot define an evidence-based list of circumstances in which BPC-157 can be assumed safe, particularly where reproductive or cancer-related risks are the concern.[8]

Read in the peptide guide
BPC-157 · InteractionsCan BPC-157 be combined safely with medicines or other peptides?
Quick answer:

The human reports were not designed to establish drug-interaction safety.[1][11] Rat experiments involving corticosteroids do not establish compatibility in people.[5] Observations involving more than one treatment do not establish that a combination is safe or that the treatments act independently.[1][11] The reviewed human evidence consequently does not support a validated interaction list or a general assurance that adding BPC-157 to an existing regimen is safe.[1][11]

Read in the peptide guide
BPC-157 · Forms & dosingWhat human absorption data are available for different routes?
Quick answer:

FDA's 2026 review found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal BPC-157.[8] This limits the ability to translate a dose used in one setting into an equivalent dose for another route.[8] A clinical dosing recommendation would require evidence connecting a defined formulation and exposure to a meaningful benefit and an acceptable safety profile, which this assessment does not establish for those routes.[8]

Read in the peptide guide
BPC-157 · Results & stoppingHow quickly should results appear, and what happens after stopping?
Quick answer:

The knee-pain report used variable retrospective follow-up, so it cannot establish a reliable healing timeline or cycling schedule.[1] The clinical-note preprint recorded discontinuation for several reasons but did not test a tapering or withdrawal protocol.[10] Retrospective reports of improvement cannot determine the expected time to benefit for a new patient or show whether symptom changes correspond to healed tissue.[1] Likewise, records of discontinuation do not establish whether tapering is necessary or whether a particular cycle reduces adverse effects.[10]

Read in the peptide guide
BPC-157 · Product qualityDoes a certificate of analysis establish product quality?
Quick answer:

FDA’s assessment identified inconsistent substance naming and incomplete impurity characterization.[8] For injectable products, it also identifies sterility, bacterial endotoxins and particulates as relevant quality attributes; a purity percentage alone does not cover those attributes.[8] Identity, impurity characterization and the quality requirements of the intended route are separate questions; a reported percentage of chemical purity addresses only part of that assessment.[8] Even an analytically characterized substance does not establish that the finished formulation is clinically effective or safe for a particular use.[8]

Read in the peptide guide
BPC-157 · StatusWhat is the U.S. regulatory status described by FDA?
Quick answer:

FDA's 2026 briefing states that neither BPC-157 free base nor BPC-157 acetate is a component of an FDA-approved drug.[8] At the October 3, 2026 source check, FDA’s risk page listed BPC-157 under nominations withdrawn by their nominators.[14]

Read in the peptide guide
TB-500 · SafetyHas the TB-500 fragment been shown safe in people?
Quick answer:

For TB-500, FDA reports no identified human exposure data and flags possible immunogenicity associated with aggregation and peptide impurities.[14]

Read in the peptide guide
TB-500 · ContraindicationsWhich populations have established safety or contraindications?
Quick answer:

FDA's assessment does not establish a safe population for the TB-500 fragment, including pregnancy, breastfeeding or people with serious medical conditions.[14]

Read in the peptide guide
TB-500 · InteractionsAre combinations with medicines or BPC-157 established as safe?
Quick answer:

The cited RGN-259 trial tested full-length thymosin beta-4 eye drops, not interactions involving the injected TB-500 fragment.[32] The four-person combination subgroup in the BPC-157 knee report used a product described as thymosin beta-4 and cannot establish the safety of fragment-containing combinations.[1]

Read in the peptide guide
TB-500 · Forms & dosingIs TB-500 interchangeable with full-length thymosin beta-4?
Quick answer:

FDA identifies TB-500 as the thymosin beta-4 fragment LKKTETQ.[14] RGN-259 research used full-length thymosin beta-4 in an ophthalmic formulation; its study regimen does not establish an injectable fragment dose.[32]

Read in the peptide guide
TB-500 · Results & stoppingDo human trials establish a recovery timeline or stopping schedule?
Quick answer:

In the 18-person trial of full-length thymosin beta-4 eye drops, the prespecified four-week healing comparison was not statistically significant, although a secondary assessment favored treatment two weeks after cessation.[32] These corneal findings do not establish an injury-recovery timeline, durable benefit or stopping schedule for injected TB-500 fragment.[32]

Read in the peptide guide
TB-500 · Product qualityWhat does a tested or compounded label establish?
Quick answer:

FDA's fragment assessment flags aggregation and peptide impurities.[14] Separately, FDA explains that compounded medicines are not reviewed before marketing for safety, effectiveness or quality, and contamination or incorrect strength can cause serious harm.[30]

Read in the peptide guide
TB-500 · StatusHow does FDA currently list the TB-500 fragment?
Quick answer:

FDA currently places thymosin beta-4 fragment LKKTETQ, also called TB-500, among withdrawn bulk-substance nominations.[14] Compounding itself does not confer FDA approval on the resulting medicine.[30]

Read in the peptide guide
GHK-Cu · SafetyAre topical and injectable GHK-Cu equally well characterized for safety?
Quick answer:

FDA identifies limited human safety data for injectable GHK-Cu and potential immunogenicity associated with aggregation and peptide impurities.[14] The cited skin trial studied topical products after laser resurfacing and cannot establish injection safety.[16]

Read in the peptide guide
GHK-Cu · ContraindicationsDoes the evidence establish safety during pregnancy or with copper-handling disorders?
Quick answer:

The cited topical trial reports cosmetic outcomes in 13 completers; its abstract does not establish safety during pregnancy, breastfeeding or in copper-handling disorders.[16]

Read in the peptide guide
GHK-Cu · InteractionsAre interactions with medicines, supplements or other peptides established?
Quick answer:

The cited trial compared topical skin-care regimens, not medication combinations; it does not establish compatibility with copper supplements, chelators or injectable peptide combinations.[16]

Read in the peptide guide
GHK-Cu · Forms & dosingCan a topical study supply an injection dose or mixing protocol?
Quick answer:

The cited randomized study examined topical GHK-Cu skin care after CO2 laser resurfacing; it provides no tested injection dose or injectable-combination protocol.[16]

Read in the peptide guide
GHK-Cu · Results & stoppingHow long do results take, and do they persist after stopping?
Quick answer:

At 12 weeks, the 13-completer topical trial found no significant between-group objective improvement in wrinkles or overall skin quality, although patient-reported satisfaction favored GHK-Cu.[16] The abstract does not report a controlled withdrawal comparison establishing persistence after stopping.[16]

Read in the peptide guide
GHK-Cu · Product qualityWhat quality concerns apply to injectable products?
Quick answer:

FDA specifically identifies aggregation and peptide impurities as concerns for injectable GHK-Cu.[14] FDA also warns that contamination or incorrect strength in compounded medicines can cause serious harm.[30]

Read in the peptide guide
GHK-Cu · StatusDoes cosmetic availability mean GHK-Cu is an approved injectable medicine?
Quick answer:

FDA lists injectable GHK-Cu among withdrawn bulk-substance nominations.[14] U.S. cosmetic products generally do not undergo FDA preapproval, except certain color additives; therapeutic claims can cause a product marketed as a cosmetic to qualify as a drug.[33]

Read in the peptide guide
CJC-1295 · SafetyWhat safety problems have been reported with CJC-1295?
Quick answer:

FDA identifies increased heart rate and systemic vasodilatory reactions among serious events associated with CJC-1295, while emphasizing the limited clinical data.[14] Its 2024 assessment also describes injection-site reactions, headache, flushing, dizziness and low blood pressure in early studies; the long-term safety profile remains unknown.[34]

Read in the peptide guide
CJC-1295 · ContraindicationsWho should avoid CJC-1295, and are contraindications established?
Quick answer:

The cited trials enrolled healthy adults aged 21–61; that study population does not establish a complete contraindication list or suitability for people with medical conditions.[17] FDA found no data informing pediatric safety and identified gaps in reproductive and long-term safety research, so these populations cannot be assumed safe on the basis of the adult trials.[34]

Read in the peptide guide
CJC-1295 · InteractionsDoes research establish that CJC-1295 is safe to combine with ipamorelin?
Quick answer:

Separate human experiments found that CJC-1295 increased GH and IGF-1 and that ipamorelin stimulated GH, but these cited experiments did not test the combination.[17][18] Our interpretation is that these hormone-response findings cannot establish the safety or added clinical benefit of combining the two.[17][18]

Read in the peptide guide
CJC-1295 · Forms & dosingAre CJC-1295 with DAC and without DAC interchangeable?
Quick answer:

FDA distinguishes CJC-1295 substances with and without a drug affinity complex (DAC), and notes that published clinical references appear to involve DAC-containing material without specifying its salt form.[34] Consequently, the long-acting trial cannot establish an interchangeable dosing schedule for products labeled without DAC.[17][34]

Read in the peptide guide
CJC-1295 · Results & stoppingHow long do CJC-1295 effects last, and what happens after stopping?
Quick answer:

In the early trials, the estimated half-life was 5.8–8.1 days, and mean IGF-1 remained above baseline for up to 28 days after repeated administration.[17] These measurements describe drug exposure and hormone responses; they do not establish durable improvements in recovery or body composition after treatment ends.[17]

Read in the peptide guide
CJC-1295 · Product qualityWhat does a purity claim establish about a CJC-1295 product?
Quick answer:

FDA found that certificates it reviewed for CJC-1295 DAC free base often reported purity without an impurity profile, and concluded that this material was not well characterized.[34] FDA separately warns that contamination or incorrect active-ingredient amounts in compounded drugs can cause serious harm, so a purity percentage alone cannot establish finished-product safety.[30]

Read in the peptide guide
CJC-1295 · StatusWhat is the US regulatory status of CJC-1295?
Quick answer:

At the October 3, 2026 check, FDA listed CJC-1295 among withdrawn compounding nominations while retaining its safety warning.[14] That compounding entry is not a drug approval: FDA states that compounded drugs are not FDA-approved and undergo no premarket agency review for safety, effectiveness or quality.[30]

Read in the peptide guide
Ipamorelin · SafetyWhat safety concerns have been reported with ipamorelin?
Quick answer:

FDA flags serious events, including death, reported during intravenous ipamorelin research for gastric motility; this wording does not establish that ipamorelin caused every event.[14] The agency also says evidence is insufficient to characterize harm through certain other injectable routes.[14] The published postoperative trial studied hospitalized surgical patients, so its safety observations cannot establish the safety of long-term use in healthy people.[19]

Read in the peptide guide
Ipamorelin · ContraindicationsDoes ipamorelin research define who should not use it?
Quick answer:

The early pharmacology study enrolled healthy men, while the postoperative trial enrolled adults undergoing bowel resection.[18][19] Those selected populations do not establish a validated contraindication list or demonstrate suitability during pregnancy or childhood; study eligibility should not be presented as a clinical prescribing rule.[18][19]

Read in the peptide guide
Ipamorelin · InteractionsCan ipamorelin interaction risks be inferred from its GH response?
Quick answer:

The pharmacology study measured ipamorelin and GH after infusion; it did not test coadministration with CJC-1295.[18] Our interpretation is that these hormone measurements cannot establish combination safety, added benefit or dose adjustments.[18]

Read in the peptide guide
Ipamorelin · Forms & dosingDo the published ipamorelin trials establish a subcutaneous dosing protocol?
Quick answer:

The cited pharmacology study and postoperative trial used intravenous infusion, with the surgical trial administering treatment in hospital for up to seven days or until discharge.[18][19] Those study regimens do not validate a subcutaneous home-use schedule or a mixture containing other peptides.[18][19]

Read in the peptide guide
Ipamorelin · Results & stoppingHow quickly does ipamorelin act, and do benefits persist after stopping?
Quick answer:

In healthy men receiving intravenous ipamorelin, its terminal half-life was about two hours and GH rose transiently before declining.[18] In the postoperative randomized trial, ipamorelin did not significantly improve the primary or secondary efficacy measures; neither study establishes lasting recovery benefits after stopping.[18][19]

Read in the peptide guide
Ipamorelin · Product qualityWhy is ipamorelin product characterization important?
Quick answer:

FDA identifies potential immune reactions related to aggregation or peptide impurities, and notes that ipamorelin’s unnatural amino acids complicate characterization.[14] For compounded products generally, FDA also warns that contamination or excessive active ingredient can cause serious injury; a product’s availability does not establish its quality.[30]

Read in the peptide guide
Ipamorelin · StatusWhat is the US regulatory status of ipamorelin acetate?
Quick answer:

At the October 3, 2026 check, ipamorelin acetate remained in FDA’s 503B Category 2 and also appeared among withdrawn nominations.[14] These compounding classifications do not constitute approval: compounded drugs are not FDA-approved or reviewed by the agency before marketing for safety, effectiveness and quality.[30]

Read in the peptide guide
Collagen peptides · SafetyCan oral collagen peptides cause adverse reactions?
Quick answer:

A published case documented anaphylaxis from fish-collagen gummies in a child with fish allergy, with the reaction confirmed by a supervised oral challenge.[35] An eight-week skin trial in 69 adult women cannot estimate rare reactions or establish long-term safety across all collagen sources and products.[26]

Read in the peptide guide
Collagen peptides · ContraindicationsWho needs particular caution with collagen supplements?
Quick answer:

Known allergy to the source material matters: the challenge-confirmed fish-collagen case demonstrates that processing collagen into a supplement does not guarantee removal of allergenic potential.[35] FDA advises discussing supplement use with a health professional during pregnancy or breastfeeding; this general precaution is not an established collagen-specific contraindication.[36]

Read in the peptide guide
Collagen peptides · InteractionsAre collagen supplements compatible with every medication?
Quick answer:

FDA advises reviewing supplements alongside medicines because some supplement ingredients can change drug absorption, metabolism or elimination.[36] That general warning does not demonstrate a specific collagen–drug interaction, but it supports checking the complete formulation and medication list instead of assuming that every collagen product is compatible.[36]

Read in the peptide guide
Collagen peptides · Forms & dosingDoes one collagen trial establish a dose for every product?
Quick answer:

The skin trial tested a specific oral collagen hydrolysate for eight weeks, so its results concern that preparation and study population rather than every collagen formulation.[26] FDA states that supplement serving sizes are set by manufacturers rather than approved by the agency; a label serving is not an independently validated clinical dose.[37]

Read in the peptide guide
Collagen peptides · Results & stoppingWhen might collagen results appear, and do they last after stopping?
Quick answer:

In one skin trial, measurements were taken at four and eight weeks, followed by a skin-elasticity assessment four weeks after the final intake.[26] The authors reported improved elasticity and some persistence in older participants, but moisture outcomes were not statistically significant and this short follow-up cannot establish permanent changes.[26]

Read in the peptide guide
Collagen peptides · Product qualityWhat information matters when evaluating a collagen supplement?
Quick answer:

FDA requires supplement manufacturing controls addressing identity, purity, quality, strength and composition, along with ingredient labeling.[37] The animal source is relevant to allergy risk, as demonstrated by the fish-collagen anaphylaxis case.[35] FDA does not test supplements before sale, so a label or legal availability does not establish batch-level verification or clinical benefit.[37]

Read in the peptide guide
Collagen peptides · StatusAre oral collagen supplements FDA-approved treatments?
Quick answer:

When a collagen product is marketed as a dietary supplement in the United States, FDA does not approve it before sale.[37] A supplement promoted to treat, prevent or cure a disease meets the drug definition, while an ordinary structure/function claim is not an FDA-approved treatment claim.[37]

Read in the peptide guide

References

37 sources
  1. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (2021)Primary researchRead review · DraftSave study
  2. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (2026)Primary research · PreclinicalRead review · DraftSave study
  3. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats (2025)Primary research · PreclinicalReview status · PendingSave study
  4. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats (2021)Primary research · PreclinicalReview status · PendingSave study
  5. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application (2010)Primary research · PreclinicalReview status · PendingSave study
  6. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats (2004)Primary research · PreclinicalReview status · PendingSave study
  7. Robert’s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157 (2021)Primary research · PreclinicalReview status · PendingSave study
  8. FDA Briefing Document: BPC-157-related bulk drug substances, July 2026 Pharmacy Compounding Advisory Committee (2026)Regulatory assessmentSave study
  9. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (2024)Primary research · Human studyRead review · DraftSave study
  10. Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes (2026)Primary research · Preprint, not peer reviewedReview status · PendingSave study
  11. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (2025)Primary research · Human studyRead review · DraftSave study
  12. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts (2014)Primary research · PreclinicalRead review · DraftSave study
  13. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs (2022)Primary research · PreclinicalReview status · PendingSave study
  14. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Accessed 2026-10-03)Regulatory guidanceSave study
  15. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (2023)Primary researchReview status · PendingSave study
  16. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (2006)Primary researchReview status · PendingSave study
  17. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (2006)Randomized controlled trialsReview status · PendingSave study
  18. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (1999)Human pharmacology studyReview status · PendingSave study
  19. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (2014)Randomized controlled trialReview status · PendingSave study
  20. Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021)Primary researchReview status · PendingSave study
  21. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022)Primary researchReview status · PendingSave study
  22. Tirzepatide Once Weekly for the Treatment of Obesity (2022)Primary researchReview status · PendingSave study
  23. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (2025)Primary researchReview status · PendingSave study
  24. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (2024)Primary researchReview status · PendingSave study
  25. 24-Week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint pain (2008)Primary researchReview status · PendingSave study
  26. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study (2014)Randomized controlled trialReview status · PendingSave study
  27. Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases (2024)Primary researchReview status · PendingSave study
  28. WEGOVY U.S. Prescribing Information, revised June 2026 (2026)Regulatory labelingSave study
  29. FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (Accessed 2026-10-03)Regulatory assessmentSave study
  30. Understanding the Risks of Compounded Drugs (Accessed 2026-10-03)Regulatory guidanceSave study
  31. ZEPBOUND U.S. Prescribing Information, revised August 2026 (2026)Regulatory labelingSave study
  32. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (2023)Primary researchReview status · PendingSave study
  33. Cosmetics & U.S. Law (Accessed 2026-10-03)Regulatory guidanceSave study
  34. December 4, 2024 Pharmacy Compounding Advisory Committee Meeting: FDA presentation on CJC-1295 (2024)Regulatory assessmentSave study
  35. A case of pediatric anaphylaxis caused by gummy tablets containing fish collagen (2020)Case reportReview status · PendingSave study
  36. Mixing Medications and Dietary Supplements Can Endanger Your Health (Accessed 2026-10-03)Regulatory guidanceSave study
  37. Questions and Answers on Dietary Supplements (Accessed 2026-10-03)Regulatory guidanceSave study

Selected public discussions help us choose questions. They are not clinical evidence. Explore discussions